Form 4: Steven Barg Increases Stake in Charles River Labs

Director Steven Barg acquired 422 shares of Charles River Laboratories International, Inc. as part of a stock-based compensation plan for director service fees.

Summary

• Steven Barg, a member of the Board of Directors, acquired 422 shares of common stock on June 2, 2026.
• The shares were granted as restricted stock units (RSUs) in lieu of cash director service fees for the term starting May 5, 2026.
• The transaction was valued at a price of $174.79 per share, representing a total grant value of approximately $73,761.
• Following this transaction, Steven Barg directly owns a total of 3,287 shares in the company.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive because the director is opting for equity over cash, though it is a routine compensation event.

Positives

• Director compensation is being paid in equity rather than cash, which aligns management interests with those of shareholders.
• The reporting person has increased their total beneficial ownership to 3,287 shares.

Negatives

• The grant is subject to a one-year vesting period, meaning the shares are not immediately liquid or owned outright without restriction.

Risks

• The value of the compensation is tied to the market price of CRL stock, which may fluctuate before the vesting date of June 2, 2027.
• Vesting is contingent upon continued service on the Board of Directors through the next annual meeting.

Future Outlook

The restricted stock units are expected to vest on June 2, 2027, or the business day prior to the company's next annual meeting of shareholders, whichever comes first.

Management Comments

• The grant was made in lieu of director service fees for the term commencing May 5, 2026.

Industry Context

StockSavvy.ai notes that equity-based compensation for directors is a standard practice among S&P 500 companies, particularly in the life sciences sector, to ensure board members maintain a long-term perspective on company valuation.

Comparison to Industry Standards

• Charles River Laboratories' use of RSUs for director retainers is consistent with peers such as IQVIA Holdings and Laboratory Corporation of America.
• The grant value is in line with median non-employee director compensation for mid-to-large cap healthcare service providers.

Corporate Governance

Related Party Transactions

• The issuance of stock to a director as compensation is a standard related-party transaction disclosed in Form 4 filings.

Stakeholder Impact

• Shareholders may see this as a positive sign of director commitment to the company's long-term stock performance.

Next Steps

• Vesting of the 422 restricted stock units on June 2, 2027.

Key Dates

Recommendation

This filing reflects standard internal compensation and does not provide new material information regarding the company's operational performance or market position.

Keywords

Charles River Laboratories, CRL, Insider Trading, Director Compensation, Restricted Stock Units, Steven Barg, SEC Form 4